Pfizer, UK National Institute for Health Research Biomedical Research Centre.

ObjectivesTo review systematically the evidence of age-related macular degeneration (AMD) affecting real-world visual ability and quality of life (QoL). To explore trends in specific topics within this body of the literature.DesignSystematic review.MethodsA systematic literature search was carried out using MEDLINE, EMBASE, CINAHL, PsycINFO, PsychARTICLES and Health and Psychosocial Instruments for articles published up to January 2015 for studies including people diagnosed with AMD, assessing real-world visual ability or QoL as an outcome. Two researchers screened studies for eligibility. Details of eligible studies including study design, characteristics of study population and outcomes measured were recorded in a data extraction table. All included studies underwent quality appraisal using the Mixed Methods Appraisal Tool 2011 Version (MMAT).ResultsFrom 5284 studies, 123 were eligible for inclusion. A range of approaches were identified, including performance-based methods, quantitative and qualitative patient-reported outcome measures (PROMs). AMD negatively affects tasks including mobility, face recognition, perception of scenes, computer use, meal preparation, shopping, cleaning, watching TV, reading, driving and, in some cases, self-care. There is evidence for higher rates of depression among people with AMD than among community dwelling elderly. A number of adaptation strategies have been associated with AMD of varying duration. Much of the research fails to report the type of AMD studied (59% of included studies) or the duration of disease in participants (74%). Of those that do report type studied, the breakdown is as follows: wet AMD 20%, dry AMD 4% and both types 17%.ConclusionsThere are many publications highlighting the negative effects of AMD in various domains of life. Future research should focus on delivering some of this research knowledge into patient management and clinical trials and differentiating between the types of AMD.

BackgroundGlaucoma is a progressive eye disease and a leading cause of visual disability. Automated assessment of the visual field determines the different stages in the disease process: it would be desirable to link these measurements taken in the clinic with patient's actual function, or establish if patients compensate for their restricted field of view when performing everyday tasks. Hence, this study investigated eye movements in glaucomatous patients when viewing driving scenes in a hazard perception test (HPT).Methodology/Principal FindingsThe HPT is a component of the UK driving licence test consisting of a series of short film clips of various traffic scenes viewed from the driver's perspective each containing hazardous situations that require the camera car to change direction or slow down. Data from nine glaucomatous patients with binocular visual field defects and ten age-matched control subjects were considered (all experienced drivers). Each subject viewed 26 different films with eye movements simultaneously monitored by an eye tracker. Computer software was purpose written to pre-process the data, co-register it to the film clips and to quantify eye movements and point-of-regard (using a dynamic bivariate contour ellipse analysis). On average, and across all HPT films, patients exhibited different eye movement characteristics to controls making, for example, significantly more saccades (P<0.001; 95% confidence interval for mean increase: 9.2 to 22.4%). Whilst the average region of ‘point-of-regard’ of the patients did not differ significantly from the controls, there were revealing cases where patients failed to see a hazard in relation to their binocular visual field defect.Conclusions/SignificanceCharacteristics of eye movement patterns in patients with bilateral glaucoma can differ significantly from age-matched controls when viewing a traffic scene. Further studies of eye movements made by glaucomatous patients could provide useful information about the definition of the visual field component required for fitness to drive.

This modeling exercise indicates that most patients in glaucoma clinics are not at high risk of progressing to statutory blindness. The likelihood of patients suffering impairment in their lifetimes is linked to VF loss at presentation, which illuminates the importance of reliably detecting significant VF defects in primary care.

PURPOSE. Evaluation of progressive visual field (VF) damage is often based on pointwise sensitivity data from standard automated perimetry; however, frequency-of seeing and test-retest studies demonstrate that these measurements can be highly variable, especially in areas of damage. The aim of this study was to characterize VF variability by the level of sensitivity using a statistical method to quantify heteroscedasticity. METHODS.A total of 14,887 Humphrey 24-2 SITA Standard VFs from 2736 patients (2736 eyes) attending Moorfields Eye Hospital from 1997 to 2009 were studied retrospectively. The VF series of each eye was analyzed using pointwise linear regression of sensitivity over time, with residuals (difference from fitted-value) from each regression pooled according to both observed and fitted sensitivities. RESULTS.The median (interquartile range) patient age, follow-up, and series length was 64 (54-71) years, 5.5 (3.9-7.0) years, and 6 (5-7) VFs, respectively. The inferred variability as a function of fitted-sensitivity was in good agreement with previous estimates. Variability was also described as a function of measured sensitivity, which confirmed that variability increased rapidly as the observed sensitivity decreased.CONCLUSIONS. This study highlights a new approach for characterizing VF variability by the level of sensitivity. A considerable strength of the method is that inference is based on thousands of clinic patients rather than the tens of subjects in test-retest studies. The results can help distinguish real VF progression from measurement variability and will be used in models for glaucoma progression detection. (Invest Ophthalmol Vis Sci. 2012;53:5985-5990)